Pfizer's suffering from generics, but 'innovation for growth'—not big M&A—is still the mantra

Pfizer’s M&A strategy is always a topic of interest, but that interest has ramped up with the company’s recent CEO switch. So far, though, new chief Albert Bourla is sticking with the company line when it comes to deal-making—even in the face of a 2019 revenue forecast that's essentially flat.